[Infostock Daily= Reporter Park Hyo-sun] US biotech company Moderna has entered a Phase 2 clinical trial for the development of the Corona 19 vaccine.
Moderna administered vaccine candidate substances(mRNA-1273) to the first participants in Phase 2 clinical trials.
A total of 600 participants were divided into two groups(18 to 55 years old and 55 years old or older) according to their age, and 300 people were each selected.
As a result of the first phase clinical trial, Corona 19 antibodies formed in all the 45 participants.
Moderna plans to start Phase 3 clinical trials in July.
Reporter Park Hyo-sun hs1351@infostock.co.kr
저작권자 © 인포스탁데일리 무단전재 및 재배포 금지
